NCT07200414|Completed
Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP)
SHARP
Loading search results
SHARP
Sponsor study identifier
interventional
12,654
1 country
1
Study Start
October 1, 2024
Actual (reported)Primary Completion
December 31, 2025
Actual (reported)Study Completion
December 31, 2025
Actual (reported)The goal of this clinical trial is to learn whether adding adolescent health services to routine government health programs can increase Human Papillomavirus (HPV) vaccination coverage among 9-year-old girls and improve use of other health services by adolescents in Nigeria. The main questions it aims to answer are: Does offering an integrated package of adolescent health services increase the proportion of 9-year-old girls who receive the HPV vaccine? Does this package increase use of other services such as reproductive health counseling, nutrition and vision screening, mental health services, and deworming among girls and boys ages 9-15 years? Researchers will compare areas that receive the integrated package to areas that continue with the standard government services to see if the intervention improves vaccination and health service use. Participants will: Be surveyed about HPV vaccination and health service use before and after the program is offered. Take part in interviews or focus groups about experiences with adolescent health services. Be offered HPV vaccination and other adolescent health services through local health facilities.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2025
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 1, 2024
Actual (reported)September 23, 2025
Actual (reported)October 1, 2025
Actual (reported)December 31, 2025
Actual (reported)December 31, 2025
Actual (reported)Change in HPV vaccine coverage among 9-year-old girls from baseline to endline
Human Papillomavirus Virus (HPV) vaccine coverage will be assessed among 9-year-old girls in intervention and comparison (Local Government Areas (LGAs) using baseline and endline household surveys of mother-daughter dyads, supported by administrative vaccination records from health facilities. Differences between baseline and endline coverage in intervention LGAs will be compared with those in comparison LGAs to estimate the impact of the integrated adolescent health package.
Baseline, 14 months
Proportion of 9-year-old girls who received at least one dose of HPV vaccine
Assessed using baseline and endline household surveys and service delivery data. Coverage will be calculated as the number of eligible girls who received at least one dose divided by the total eligible girls surveyed.
Baseline, 14 months
Local government areas (LGAs) where the routine government health system delivers an integrated package of adolescent health services. The package includes HPV vaccination, sexual and reproductive health counseling, general health check-ups, nutrition and vision screening, mental health support, deworming, and dental and oral health services.
Local government areas (LGAs) where only standard government health services are provided. HPV vaccination and other adolescent health services are delivered according to routine practice without the additional integrated package.
Delivery of an integrated package of adolescent health services through government health facilities. The package includes HPV vaccination, sexual and reproductive health counseling, general health check-ups, nutrition and vision screening, mental health support, deworming, and dental and oral health services. Implemented in intervention LGAs in Lagos and Kebbi States.
Lagos State Ministry of Health/Kebbi State Ministry of Health
Lagos, Nigeria
Adeyanju GC, Essoh TA, Sidibe AR, Kyesi F, Aina M. Human Papillomavirus Vaccination Acceleration and Introduction in Sub-Saharan Africa: A Multi-Country Cohort Analysis. Vaccines (Basel). 2024 May 1;12(5):489. doi: 10.3390/vaccines12050489.
Lawson O, Ameyan L, Tukur Z, Dunu S, Kerry M, Okuyemi OO, Yusuf Z, Fasawe O, Wiwa O, Hebert KS, Joseph JT, Nwokwu UE, Okpako O, Chime CI. Cervical cancer screening outcomes in public health facilities in three states in Nigeria. BMC Public Health. 2023 Sep 1;23(1):1688. doi: 10.1186/s12889-023-16539-1.
Chizoba Wonodi, MBBS, DrPH, MPH
Johns Hopkins University
12,654 participants (actual enrollment reported by the registry).
First Submitted
September 23, 2025
First Posted
October 1, 2025
Study Start
October 1, 2024
Actual (reported)AFIX to Improve HPV Vaccination
Proportion of adolescents aged 9-15 who report use of at least one adolescent health service
Baseline, 14 months
Routine government health services provided in comparison LGAs. Services may include HPV vaccination as per national immunization schedules and other adolescent health services delivered under existing programs, but without the integrated package.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023 Feb;11(2):e197-e206. doi: 10.1016/S2214-109X(22)00501-0. Epub 2022 Dec 14.
Primary Completion
December 31, 2025
Actual (reported)Study Completion
December 31, 2025
Actual (reported)Last Updated
April 13, 2026
Record last verified: 2026-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: